134 related articles for article (PubMed ID: 15619007)
21. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells.
Li J; Wood WH; Becker KG; Weeraratna AT; Morin PJ
Oncogene; 2007 May; 26(20):2860-72. PubMed ID: 17072341
[TBL] [Abstract][Full Text] [Related]
22. Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53.
Wyllie FS; Haughton MF; Rowson JM; Wynford-Thomas D
Br J Cancer; 1999 Mar; 79(7-8):1111-20. PubMed ID: 10098744
[TBL] [Abstract][Full Text] [Related]
23. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
24. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
25. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
26. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
Puskas LG; Juhasz F; Zarva A; Hackler L; Farid NR
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(2):177-86. PubMed ID: 16171553
[TBL] [Abstract][Full Text] [Related]
27. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status.
Moretti F; Nanni S; Farsetti A; Narducci M; Crescenzi M; Giuliacci S; Sacchi A; Pontecorvi A
J Clin Endocrinol Metab; 2000 Jan; 85(1):302-8. PubMed ID: 10634403
[TBL] [Abstract][Full Text] [Related]
28. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.
Asada N; Tsuchiya H; Tomita K
Anticancer Res; 1999; 19(6B):5131-7. PubMed ID: 10697522
[TBL] [Abstract][Full Text] [Related]
29. Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo.
Ren X; Liu H; Zhang M; Wang M; Ma S
Mol Med Rep; 2016 Sep; 14(3):2431-8. PubMed ID: 27484725
[TBL] [Abstract][Full Text] [Related]
30. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells.
Namba H; Hara T; Tukazaki T; Migita K; Ishikawa N; Ito K; Nagataki S; Yamashita S
Cancer Res; 1995 May; 55(10):2075-80. PubMed ID: 7743505
[TBL] [Abstract][Full Text] [Related]
31. Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation.
Deplanque G; Céraline J; Lapouge G; Dufour P; Bergerat JP; Klein-Soyer C
Biochem Biophys Res Commun; 2004 Feb; 314(4):1100-6. PubMed ID: 14751246
[TBL] [Abstract][Full Text] [Related]
32. APM2 is a novel mediator of cisplatin resistance in a variety of cancer cell types regardless of p53 or MMR status.
Scott BJ; Qutob S; Liu QY; Ng CE
Int J Cancer; 2009 Sep; 125(5):1193-204. PubMed ID: 19444912
[TBL] [Abstract][Full Text] [Related]
33. The effects of wild-type p53 gene transfection on the growth and chemotherapeutic sensitivity of human glioma cells.
Xiang W; Zhu X; Zhao H
J Huazhong Univ Sci Technolog Med Sci; 2002; 22(1):44-6. PubMed ID: 12658781
[TBL] [Abstract][Full Text] [Related]
34. [Effects of wild-type p53 gene transfection on the growth and cisplatin sensitivity of cervical cancer cell line HeLa].
Wang X; Peng Z; Wang H
Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):40-2. PubMed ID: 12599424
[TBL] [Abstract][Full Text] [Related]
35. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
36. Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes.
Wang H; Yu Y; Chen C; Wang Q; Huang T; Hong F; Zhu L
Mol Med Rep; 2015 Aug; 12(2):2503-10. PubMed ID: 25955318
[TBL] [Abstract][Full Text] [Related]
37. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
[TBL] [Abstract][Full Text] [Related]
38. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma.
Tsai LL; Yu CC; Chang YC; Yu CH; Chou MY
J Oral Pathol Med; 2011 Sep; 40(8):621-8. PubMed ID: 21342274
[TBL] [Abstract][Full Text] [Related]
39. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
40. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.
Zhang P; Zhang Z; Zhou X; Qiu W; Chen F; Chen W
BMC Cancer; 2006 Sep; 6():224. PubMed ID: 16978399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
